Initial Efficacy Data for GlycoMimetics’ GMI-1271 Combined with Chemotherapy in Patients with AML to Be Presented at European Hematology Association 21st Congress

ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that initial efficacy
data from a Phase 1/2 clinical trial on the effects of drug candidate
GMI-1271 combined with chemotherapy on patients with acute myeloid
leukemia (AML) were accepted as a poster to be presented at the European
Hematology Association’s 21st
Congress, taking place June 9-12 in Copenhagen, Denmark.
The poster (P191), entitled “Results of a Phase 1 study of GMI-1271, a
novel E-selectin antagonist in combination with induction chemotherapy
in relapse/refractory AML: a novel, well-tolerated regimen with a high
remission rate,” is scheduled for 5:15 p.m. CET on Friday, June 10.
The abstract is available here
About GMI-1271
GMI-1271 is designed to block E-selectin (an adhesion molecule on cells
in the bone marrow) from binding with acute myeloid leukemia (AML) cells
in ways that help the cancer cells evade the effects of chemotherapy
treatment. Preclinical research points to the drug’s potential role in
moving cancerous cells out of the protective environment of the bone
marrow where they hide and escape the effects of chemotherapy. By
blocking E-selectin, GMI-1271 also may protect normal blood-producing
cells, and reduce the toxic side effects of chemotherapy such as low
white blood cell counts that make some patients more prone to
infections. GMI-1271 may also reduce mucositis (inflammation or lesions
in the intestinal tract and mouth), which can be a side effect of
chemotherapy. GlycoMimetics has announced encouraging initial top line
data from the first two cohorts in its ongoing Phase 1/2 clinical study.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on
sickle cell disease and cancer. GlycoMimetics’ first drug candidate,
rivipansel, a pan-selectin antagonist, is being developed for the
treatment of vaso-occlusive crisis in sickle cell disease and is being
evaluated in a Phase 3 clinical trial being conducted by its strategic
collaborator, Pfizer. GlycoMimetics’ wholly-owned drug candidate,
GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing
Phase 1/ 2 clinical trial as a potential treatment for AML and other
blood disorders. GlycoMimetics expects to file an IND with the FDA for a
third drug candidate, GMI-1359, a combined CXCR4 and E-selectin
antagonist, in the third quarter of 2016. GlycoMimetics is located
in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.